We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia.
- Authors
AKSU, Salih; SAHIN, Fahri; UZ, Burak; YAVUZ, Selim A.; ATAY, Hilmi; KELKITLI, Engin; TURGUT, Mehmet; PEHLIVAN, Mustafa; AKAY, Meltem O.; GURKAN, Emel; DEMIR, Muzaffer; KAHRAMAN, Selda; DEMIRKAN, Fatih; PAYDAS, Semra; SAYDAM, Güray; HAZNEDAROGLU, Ibrahim C.
- Abstract
We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose of 100 once daily. Dose adjustment were observed in 11 patients, respectively. In case of other circumstances, treatment has been continued with a lower dose if needed. The median dose of dasatinib was 100 mg daily (range: 50 to 140 mg). We conclude that even low-dose dasatinib therapy is an effective and safe in second line treatment of CML patients patients.
- Subjects
TREATMENT of chronic myeloid leukemia; PATIENTS; CHRONIC diseases; DRUG dosage; THERAPEUTICS; CLINICAL medicine
- Publication
UHOD: International Journal of Hematology & Oncology / Uluslararasi Hematoloji Onkoloji Dergisi, 2012, Vol 22, p8
- ISSN
1306-133X
- Publication type
Article
- DOI
10.4999/uhod.12004